Search

Your search keyword '"Perez, Alba"' showing total 280 results
Start Over Author "Perez, Alba"
280 results on '"Perez, Alba"'

7. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

Author

Abe, Wakana, Adan De Varona, Tania, Adiatullina, Daria, Aguilar Zapata, Daniel, Ahlers, Kevin, Aimo, Carolina, Akere, Ayoade, Akimova, Elena, Alatorre Alexander, Jorge, Aldrich, Logan, Ali Garcia, Ismael, Ali García, Karim, Allison, Lee, Alonso Zuñiga, Rosa, Aloysius, Ivan, Altclas, Javier, Alvarisqueta, Andres, Antila, Martti, Anton, Camila, Árboix Alamo, Elisabet, Arora, Samir, Avilés Felix, Ramón Alejandro, Bakhtina, Natalya, Barbero-Becerra, Varenka, Barragan-Reyes, Armando, Barreira, Alejandro, Barrett, Mitchell, Beran, Jiri, Berki, Nikolett, Berki, Viktoria, Betten, Richard, Binelli, Claudia, Brunzová, Lenka, Bussolari, Cecilia, Byargeon, Karianna, Bytnar, Justyna, Camberos, Carlos, Campos Corzo, Pedro, Cannon, Grazia, Canovi, Valentina, Carla da Rosa, Simone, Moser, Ana Caroline, Carrera Rivas, Luis, Casas, Marcelo Martin, Castañeda-Méndez, Paulo, Cavalcante, Ana, Cherepova, Eugenia, Chermenskii, Alexei, Clark, Lauren, Codeluppi, Mauro, Coelho, Flavia, Contreras, Belinda, Cran, Alex, Dao, Taylor, Dharma, Chrisette, Di Castri, Cosimo, Diaz Balocchi, Victoria, Durán, Omar, Earl, Kara, Ellery, Adam, Endo, Tomoko, Everding, Andrea, Fischer, Rainald, Fonseca, Benedito, Franklin, Chelsea C., Franz, Susan-Beatrice, Fumagalli, Anna, Galindo-Amaya, Mauricio, Galli, Mariagiulia, Gerna, Laura, Gil Ureña, Karolly, Gomes Antila, Henrikki, Gomes Maricato, Laura Ines, Goncalvez, Gabriela, Gonzalez, Martin, González-Lama, Jesús, Granier, Stephen, Granier, Jacob, Grunwald, Stephan, Guardeño-Ropero, David, Guberti, Monica, Guduri, Sridhar, Guerrero García, Carolina, Haggiagi, Jehad, Hale, Kacie, Hayashi, Toshimasa, Hermes, Maiara, Hernandez Colin, Dante, Hirai, Yuji, Hojo, Masayuki, Homma, Tetsuya, Hour, Billy, Huber, Andreas, Iacovelli, Diego, Ishibashi, Noriomi, Iwabe, Yutaro, Izumi, Shinyu, Jessen, Arne, Jessen, Heiko, Jeudy, Wilner, Jiménez Marcos, Marta, Johnson, Rebecca, Juárez-Hernández, Eva, Kabasawa, Kiyomi, Kamińska, Katarzyna, Kawabe, Megumi, Kemp, Angela, Khmelnitskiy, Oleg, Klassen, Carina, Kobrynska, Olena, Koleckar, Pavel, Korn, Stephanie, Kornmann, Marc, Kostenko, Viktor, Kovalchuk, Evgenii, Kovalchuk, Yana, Kümmerle, Tim, Lachmund, Ulrike, Lammersmann, Kerstin, Lastebasse, Flávio, Lattuada, Ivana, Lauer, Felicitas, Lebed, Kyrylo, Lebed, Olga, Lecona-Garcia, Diego, Leoni, Maria Christina, Lima, Marina, Little, Raymond, Little, Holly, Lizardi-Díaz, Andrea, Lobo-Becker, Michele, Luppi, Francesco, Macias, Veronica, Maesaki, Shigefumi, Magnaghi, Cristiano, Mancini, Annalisa, Mazur, Stanisław, Melnikova, Tatiana, Menchaca, Sergio, Menendez-Perez, Ibrahim, Międlar, Ewa, Mizunuma, Shuuichi, Mochalova, Anastasiya, Mohamed, Mihad, Moll, Theresa, Montalvo, Camila, Mottola, Amber, Mück, Birgit, Mussi Brugnolli, Rebeca, Nanda, Akanksha, Neuner, Dörthe, Ngwueke, Agatha, Noe, Sebastian, Novacek, Martin, Nuzzolo-Shihadeh, Laura, Obiekwe, Emeka, Ocampo Gaytán, Isaias G., Ohmagari, Norio, Ohta, Shin, Onyewuchi, Ptuonye, Pankov, Iurii, Pedrosa, Maurício, Peré, Yael, Pereyra, Alejandro, Perez, Eliana, Perez-Alba, Eduardo, Perpiña Lozano, Paloma, Perrei, Tanya, Peterson, Dena, Pierroti, Ligia, Pineda-Cárdenas, Felipe, Plascencia Sanchez, Teresa, Poletti, Camila, Pomaranzi, Chiara, Portes, Lisette, Postel, Nils, Ramirez, Monica, Ramírez, Isabel, Ramirez-Baena, Miguel, Ramjee, Mahadev, Ratti, Giovanna, Reeve, Jackie, Reichert, Petr, Reichertová, Petra, Reyes Garcia, Edgar Alejandro, Ricardo, Celso, Rodríguez Rodríguez, Nicomedes, Roldán Sánchez, Jaun, Romero-Lopez, Matilde, Rosales, Tyrone, Rosales, Harvey, Roshan, Mohamed, Roshan, Simran, Rovere Querini, Patrizia, Rutter, Heather, Sachwani, Sadaf, Sagara, Hironori, Sakai, Jun, Samson, Nina, Sánchez Mijangos, José Héctor, Sánchez, Liliana, Sánchez-González, Ana, Sandford, Micko, Santana, Laura, Santos de Carvalho, Felipe, Sasao, Reiko, Sato, Lubna, Scheuermann, Elizabeth, Schmidt, Olaf, Seki, Masafumi, Shaikh, Safia, Shimada, Daishi, Shinkai, Masaharu, Shinoda, Masahiro, Smith, Jackie, Solorzano, Fernando, Soncini, Silvia, Soregine, Katalin, Sosa, Erica, Sowade, Olalekan, Špinková, Veronika, Staniford, Ruth, Steigemann, Iska, Steiner, Vivien, Strelkov, Vladimir, Suárez Pineda, Cintya R., Suenaga, Hiroki, Suzaki, Shintaro, Swayze, Hannah, Tada, Yuji, Takeshita, Yuichiro, Takiguchi, Yasuo, Tanaka, Akihiko, Tarumoto, Norihito, Tatarintseva, Albina, Taubert, Michelle, Terenya, Elizaveta, Tinoco, César, Tomiyasu, Tomohiro, Torres-Vidal, Gladys, Trejo-Aguiar, Gabriela, Tsushima, Kenji, Tunstall, Emma, Turrà, Caterina, Valdes, Yoandy, Valencia Castro, Nelly, Visconti, Guilherme, Vitali, Giordano, Vutikullird, Apinya, Watti, Jezdancher, Werth, Doreen, Wilson, Cheyanne, Wilson, Philippe, Workman, Amy, Wörle, Pamela, Wyen, Christoph, Yamaguchi, Yoshiko, Yamamoto, Kei, Montgomery, Hugh, Hobbs, F D Richard, Padilla, Francisco, Arbetter, Douglas, Templeton, Alison, Seegobin, Seth, Kim, Kenneth, Campos, Jesus Abraham Simón, Arends, Rosalinda H, Brodek, Bryan H, Brooks, Dennis, Garbes, Pedro, Jimenez, Julieta, Koh, Gavin C K W, Padilla, Kelly W, Streicher, Katie, Viani, Rolando M, Alagappan, Vijay, Pangalos, Menelas N, and Esser, Mark T

Published
2022
Full Text
View/download PDF

13. Experiencia en España con los primeros pacientes en hemodiálisis domiciliaria tratados con monitores de bajo flujo de líquido de diálisis

Author

Slon Roblero, Maria Fernanda, Bajo Rubio, Maria Auxiliadora, González-Moya, Mercedes, Calviño Varela, Jesús, Pérez Alba, Alejandro, Villaro Gumpert, Juan, Cigarrán, Secundino, Vidau, Pedro, García Marcos, Sergio, Abáigar Luquin, Pedro, Coll Piera, Elisabet, Gascón Mariño, Antonio, Espigares, Maria José, Molina, Mariola D., and Molina, Pablo

Published
2022
Full Text
View/download PDF

15. A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19.

Author

Landete, Pedro, Caliman-Sturdza, Olga-Adriana, Lopez-Martin, Jose A, Preotescu, Liliana, Luca, Mihaela-Catalina, Kotanidou, Anastasia, Villares, Paula, Iglesias, Shirley-Patricia, Guisado-Vasco, Pablo, Saiz-Lou, Elena-Maria, Farinas-Alvarez, Maria del Carmen, Lucas, Esperanza Merino de, Perez-Alba, Eduardo, Cisneros, Jose-Miguel, Estrada, Vicente, Hidalgo-Tenorio, Carmen, Poulakou, Garyfallia, Torralba, Miguel, Fortun, Jesus, and Garcia-Ocana, Paula

Subjects
COMBINATION drug therapy, PATIENT safety, RESEARCH funding, STATISTICAL sampling, HOSPITAL care, OXYGEN therapy, TERMINATION of treatment, RANDOMIZED controlled trials, DESCRIPTIVE statistics, INVERTEBRATES, PEPTIDES, ANTIVIRAL agents, DRUG efficacy, RESEARCH, CONFIDENCE intervals, COVID-19, MARINE animals, DEXAMETHASONE, EVALUATION, ADULTS
Abstract

Background Plitidepsin has shown potent preclinical activity against severe acute respiratory syndrome coronavirus 2 and was generally well tolerated in a phase I trial of hospitalized patients with coronavirus disease 2019 (COVID-19). NEPTUNO, a phase III, multicenter, randomized, controlled trial, was designed to evaluate the efficacy and safety of plitidepsin in the management of moderate COVID-19 in hospitalized adult patients. Methods Included patients had documented severe acute respiratory syndrome coronavirus 2 infection, required oxygen therapy, and had adequate organ function. The planned sample size was 609 patients. Patients were randomized 1:1:1 to at least 3 days of dexamethasone plus either plitidepsin (1.5 mg/day or 2.5 mg/day, for 3 days) or standard of care (control). The primary endpoint was the time to sustained withdrawal of supplemental oxygen. Secondary endpoints included time to sustained hospital discharge, clinical status, duration of oxygen support, percentage of patients requiring admission to the intensive care unit, and safety. Results After randomizing 205 patients, NEPTUNO was discontinued due to a notable drop in COVID-19–related hospitalizations. Available data suggest a 2-day improvement in the median time to sustained oxygen therapy discontinuation (5 vs 7 days) favoring both plitidepsin arms (hazard ratio, 1.37; 95% confidence interval,.96–1.96; P =.08 for plitidepsin 1.5 mg vs control; hazard ratio, 1.06; 95% confidence interval,.73–1.53; P =.78 for plitidepsin 2.5 mg vs control). Plitidepsin was generally well tolerated. Conclusions Despite the trial limitations, these results suggest that plitidepsin may have a positive benefit-risk ratio in the management of patients requiring oxygen therapy. Further studies with plitidepsin, including those in immunosuppressed patients, are warranted. Results from this phase III trial suggest that plitidepsin, a first-in-class antiviral, may have a positive benefit-risk ratio in the management of hospitalized patients requiring oxygen therapy for moderate COVID-19. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection

Author

Medrano, Sara, Pérez, Alba, Galar, Alicia, Martínez-Expósito, Oscar, Alejo-Cancho, Izaskun, Martín-Higuera, M. Carmen, Rolo, Marta, Estévez, M. Jesús, Bravo, Tania, Vicente, Diego, Montes, Mila, Merino, Paloma, Guinea, Jesús, Muñoz-Gallego, Irene, González-Donapetry, Patricia, Galán, Juan Carlos, Antona, Nerea, Cilla, Gustavo, Hernáez-Crespo, Silvia, Díaz-de Tuesta, José Luis, Gual-de Torrella, Ana, González-Romo, Fernando, Escribano, Pilar, Sánchez-Castellano, Miguel Ángel, Sota-Busselo, Mercedes, Delgado-Iribarren, Alberto, García, Julio, Cantón, Rafael, Muñoz, Patricia, Folgueira, María Dolores, Cuenca-Estrella, Manuel, and Oteo-Iglesias, Jesús

Published
2021
Full Text
View/download PDF

27. Candida auris Invasive Infection after Kidney Transplantation

Author

Javier Reque, Rosa Arlandis, Nayara Panizo, Maria José Pascual, and Alejandro Perez-Alba

Subjects
Diseases of the genitourinary system. Urology, RC870-923
Abstract

Introduction. C. auris has been associated not only with a variety of invasive fungal infections, including candidemia, sometimes related to central venous catheter, but also with pericarditis and respiratory tract and urinary tract infections. Materials and Methods. We describe the case of a patient with persistent fever despite antibiotics, who presented with Candida isolation in blood cultures, typified as Candida auris species. Results. A 57-year-old male receiving peritoneal dialysis underwent kidney transplantation which was complicated by primary nonfunction due to arterial thrombosis necessitating graft nephrectomy. During the postoperative period, he presented with Pseudomonas aeruginosa pneumonia that was treated with levofloxacin and catheter-related Enterococcus faecalis bacteremia treated with linezolid. After hospital discharge, he then presented with herpes zoster infection treated with valacyclovir. Ten days later, he developed peritonitis and exit site infection with multidrug-resistant Pseudomonas aeruginosa treated with intraperitoneal aztreonam and peritoneal dialysis catheter removal. Despite broad-spectrum antibiotic therapy, the patient remained febrile. All microbiology laboratory tests were negative, so it was decided to stop antibiotic therapy for 48 hours and repeat cultures in order to avoid possible false negatives. In new blood cultures performed after suspension of antibiotic therapy, candidemia was observed, later typified as Candida auris species. After completing antifungal treatment (three weeks with intravenous amphotericin B 100 mg qd and two weeks of intravenous anidulafungin 100 mg qd), microbiological cultures remained negative and the patient made uneventful recovery. Conclusion. Candida auris invasive infection has been mainly described in patients with severe underlying comorbidities and immunocompromise. Multidrug-resistant clusters of Candida auris are increasingly emerging.

Published
2022
Full Text
View/download PDF

28. Subclinical Hypothyroidism in Advanced Chronic Kidney Disease Patients: Prevalence and Associated Factors

Author

Javier Reque Santivañez, Beatriz Garcia Peris, Nayara Panizo Gonzalez, Alejandro Perez Alba, Luis D’Marco, and Eládio Collado Boira

Subjects
Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

Introduction. Renal function and thyroid metabolism are tightly related. However, evidence about subclinical hypothyroidism prevalence in patients with chronic kidney disease and its related factors is scarce. Objectives. Our aim is to analyze subclinical hypothyroidism prevalence and its related factors in patients with advanced chronic kidney disease. Materials and methods. Nondialysis-dependent patients with chronic kidney disease at stages 3 to 5 were included. Other inclusion criteria were age above 18 years and clinical stability. Patients with diagnosed thyroid illnesses were excluded. Subclinical hypothyroidism was defined as thyroid stimulating hormone (TSH) > 5.3 mU/L, with free thyroxine 4 (FT4) between 0.54 and 1.24 ng/dl. Filiation data, comorbidities, and routine blood and urine test results were registered. Results. A total of 299 patients were included. Of them, 184 (61.5%) were men. The mean age was 71 ± 13 years old. The mean glomerular filtration rate (CKD-EPI) was 22 ± 9 ml/min/1.73 m2. According to chronic kidney disease stages, global distribution of patients was as follows: Stage 3, 67 patients (22.4%); Stage 4, 155 patients (51.8%); and Stage 5, 77 patients (25.8%). We found subclinical hypothyroidism in 54 (18.1%) patients. According to chronic kidney disease stages, distribution of affected patients was as follows: Stage 3, 9 patients (13%); Stage 4, 25 patients (16.1%); and Stage 5, 20 patients (26%). Differences among stages were statistically significant. By univariate analysis, factors related with subclinical hypothyroidism were as follows: age RR 1.048 (95% CI 1.019–1.078; p=0.001), hypertension RR 2.705 (95% CI 1.026–7.130; p=0.04), glomerular filtration rate RR 0.962 (95% CI 0.929–0.996; p=0.03), and proteinuria higher than 1 gram/day RR 2.387 (95% CI 1.303–4.374; p=0.005). By multivariate analysis adjusted by age, hypertension, glomerular filtration rate, proteinuria, diabetes, and cardiovascular disease history, only age RR 1.016 (95% CI 1.009–1.028; p=0.04) and glomerular filtration rate RR 0.963 (95% CI 0.930–0.997; p=0.03) preserved their independent association with subclinical hypothyroidism. Conclusions. Subclinical hypothyroidism prevalence in patients with chronic kidney disease is high and increases with renal disease severity. Factors independently related to subclinical hypothyroidism are age and glomerular filtration rate.

Published
2022
Full Text
View/download PDF

31. Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?

Author

Paola Bocanegra-Ibarias, Adrián Camacho-Ortiz, Elvira Garza-González, Samantha Flores-Treviño, Hyojin Kim, and Eduardo Perez-Alba

Subjects
NDM, Klebsiella pneumonia, Aztreonam, Ceftazidime-Avibactam, Colistin, Carbapenem-Resistant enterobacteria, Microbiology, QR1-502
Abstract

Objectives: We report the successful treatment of a bloodstream infection caused by Klebsiella pneumoniae harbouring NDM-1 using aztreonam-ceftazidime-avibactam in a neutropenic patient in whom colistin and meropenem therapy had previously failed. Methods: A clinical isolate was evaluated to determine the presence of NDM, TEM, SHV, CTX, and CMY, and the killing kinetics of aztreonam (ATM; 4 μg/mL), aztreonam-avibactam (ATM-AVI; 4/4 μg/mL), and colistin (2 and 4 μg/mL) were tested. Results: ATM-AVI showed in vitro activity against the Klebsiella pneumoniae harbouring NDM-1, whereas colistin allowed re-growth. Conclusions: This report supports reconsideration of use of colistin for treatment of infections caused by K. pneumoniae harbouring NDM. CZA/ATM use should be kept in mind as a treatment option, perhaps earlier than colistin.

Published
2020
Full Text
View/download PDF

32. Contributing Authors

Author

Abe, Yukio, primary, Aita, Márcio Aurélio, additional, Perez Alba, Jose Manuel, additional, Axelrod, Daniel, additional, Axelsson, Peter, additional, Bauer, Thomas, additional, Bell, Katrina R., additional, Bessems, J.H.J.M., additional, Bhandari, Mohit, additional, Blackburn, Julia, additional, Blokhuis, Taco J., additional, Boeckstyns, Michel E.H., additional, Bouyer, Michael, additional, Carratalá Baixauli, Vicente, additional, Calcagni, Maurizio, additional, Chan, Andrea, additional, Chantelot, Christophe, additional, Chiche, Léo, additional, Chung, Kevin C., additional, Colaris, Joost W., additional, Corella Montoya, Fernando, additional, Davis, Elissa S., additional, Piñal, Francisco del, additional, Dias, Joseph, additional, Doornberg, Job N., additional, Drijfhout van Hooff, C.C., additional, Duckworth, Andrew D., additional, Ehlinger, Matthieu, additional, Esposito, K.R., additional, Facca, Sybille, additional, Farnebo, Simon, additional, Fredrikson, Per, additional, Freibott, C.E., additional, Gómez, Ignacio Miranda, additional, Gouzou, Stéphanie, additional, Grewal, Ruby, additional, Guidi, Marco, additional, Hannemann, Pascal F.W., additional, Harper, Carl M., additional, Haynes, Sara F., additional, Jaarsma, R.L., additional, Johal, Herman, additional, Johnson, Nick, additional, Jung, Hyoung-Seok, additional, Kadar, Assaf, additional, Kim, Jong Pil, additional, Koehler, Steven M., additional, Laane, C.L.E., additional, Lafosse, Thibault, additional, Lee, Hyun Il, additional, Lee, Jae-Sung, additional, Lindau, Tommy R., additional, Lindqvist, Sandra, additional, Liverneaux, Philippe, additional, Loisel, François, additional, Lucas García, Francisco J., additional, Luchetti, Riccardo, additional, Meaike, Jesse D., additional, Meaike, Joshua J., additional, Medoff, Robert J., additional, Michielsen, Maartje, additional, Miller, Andrew, additional, Molyneux, Samuel G., additional, Obert, Laurent, additional, Osterman, A. Lee, additional, Paul, Ryan, additional, Pientka, William F., additional, Ploegmakers, J.J.W., additional, Pocnetz, Sasa, additional, Poublon, A.R., additional, Ring, D., additional, Rozental, Tamara, additional, Saab, Marc, additional, Saka, Natsumi, additional, Sandow, Michael J., additional, Schep, Niels W.L., additional, Schoolmeesters, B.J.A., additional, Shin, Alexander Y., additional, Shoap, S.C., additional, Sims, Laura, additional, Strauch, R.J., additional, Strelzow, Jason A., additional, Suh, Nina, additional, Takahashi, Youhei, additional, Tang, Jin Bo, additional, Ten Bosch, Jan A., additional, The, B., additional, Tosti, Rick, additional, van der Windt, A.E., additional, Vanhees, Matthias, additional, Vernet, Paul, additional, Verstreken, Frederik, additional, White, Timothy O., additional, Wijffels, M.M.E., additional, Woolnough, Taylor, additional, Xiong, Grace, additional, Zenke, Yukichi, additional, and Zhang, Yiyang, additional

Published
2021
Full Text
View/download PDF

34. Synergetic effect of hydrothermal and deep eutectic solvents (DES) pretreatments on Robinia wood fractionation for the manufacture of bioethanol and cellulose nanocrystals

Author

Perez Perez, Alba, Garcia Del Rio, Pablo, Lobato Rodriguez, Álvaro, Garrote Velasco, Gil, and Gullon Estevez, Beatriz

Subjects
2304.19 Polisacáridos, 2302.12 Fermentación, 2304.02 Celulosa
Abstract

This study dealt with the use of environmentally friendly processes based on microwave-assisted autohydrolysis (MAA) and deep eutectic solvents (DES) for the selective fractionation of Robinia pseudoacacia wood (RW) within a biorefinery approach. MAA enabled the recovery of 76% of hemicelluloses in the form of oligomers. Afterwards, different conditions were assessed for the optimal delignification of RW with the DES choline chloride combined with lactic acid reaching delignification ratios up to 86%. Two different methods were accomplished to valorize the cellulosic-rich solid fraction after delignification: (i) bioethanol via enzymatic-fermentative pathway (attaining 53.3 g ethanol/L, about 83% of ethanol yield), and (ii) cellulose nanocrystals (length of 27–550 nm, width of 2–12 nm). Hence, this study presents a novel multiproduct biorefinery to selectively separate the main components of RW and valorize its cellulosic fraction using eco-friendly procedures Universidade de Vigo/CISUG Ministerio de Economía| Ref. PID2019-110031RB-I00 Xunta de Galicia | Ref. ED431C 2017/62-GRC Ministerio de Ciencia, Innovación y Universidades | Ref. FPU21/02446 Ministerio de Ciencia, Innovación y Universidades | Ref. PRE2020-093359 Ministerio de Ciencia, Innovación y Universidades | Ref. RYC2018-026177-I Xunta de Galicia | Ref. ED481B-2022-020

Published
2023

37. Microwave-assisted autohydrolysis of avocado seed for the recovery of antioxidant phenolics and glucose

Author

Del Castillo Llamosas, Alexandra, Eibes, Gemma, Ferreira Santos, Pedro Miguel, Perez Perez, Alba, Garcia Del Rio, Pablo, and Gullon Estevez, Beatriz

Subjects
2304.19 Polisacáridos, 3303.04 Separación Química, 3303.03 Procesos Químicos
Abstract

This study describes the valorization of avocado seed (AS) within a green biorefinery concept using microwave-assisted autohydrolysis. After the treatment at temperatures of 150–230 ◦C for 5 min, the resulting solid and liquor were characterized. The temperature of 220 ◦C led to the simultaneous optimal values of antioxidant phenolics/flavonoids (42.15 mg GAE/g AS, 31.89 RE/g AS, respectively) and glucose + glucooligosaccharides (38.82 g/L) in the liquor. Extraction with ethyl acetate allowed the recovery of the bioactive compounds while maintaining the polysaccharides in the liquor. The extract was rich in vanillin (99.02 mg/g AS) and contained several phenolic acids and flavonoids. The solid phase and the phenolic-free liquor were subjected to enzymatic hydrolysis to produce glucose, reaching values of 9.93 and 105 g glucose/L, respectively. This work demonstrates that microwave-assisted autohydrolysis is a promising technology to obtain fermentable sugars and antioxidant phenolic compounds from avocado seeds following a biorefinery scheme. Universidade de Vigo/CISUG Xunta de Galicia | Ref. ED431C 2017/62-GRC Xunta de Galicia | Ref. ED431F 2020/03 Xunta de Galicia | Ref. ED481B-2022-020 Ministerio de Ciencia, Innovación y Universidades | Ref. FPU21/02446 Ministerio de Ciencia, Innovación y Universidades | Ref. FJC2021-046978-I Ministerio de Ciencia, Innovación y Universidades | Ref. RYC2018-024846-I Ministerio de Ciencia, Innovación y Universidades | Ref. RYC2018-026177-I

Published
2023

41. Health care model for people living in nursing homes based on integrated care.

Author

Espaulella-Ferrer, Mariona, Morel-Corona, Felix Jorge, Zarco-Martinez, Mireia, Marty-Perez, Alba, Sola-Palacios, Raquel, Campollo-Duquela, Maria Eugenia, Cruz-Grullon, Maricelis, Puigoriol-Juvanteny, Emma, Otero-Viñas, Marta, and Espaulella-Panicot, Joan

Subjects
HOSPITAL emergency services, FRAIL elderly, RURAL conditions, TIME, CRITICALLY ill, MATHEMATICAL models, TASK performance, PATIENTS, PATIENT-centered care, MEDICATION error prevention, HEALTH outcome assessment, NURSING care facilities, MEDICAL care use, NURSES, HEALTH care teams, HOSPITAL care, THEORY, INTEGRATED health care delivery, MEDICAL case management, PATIENT care, NEEDS assessment, MEDICAL appointments, ELDER care, MEDICAL specialties & specialists, OLD age
Abstract

Purpose: Older people living in nursing homes have complex care needs and frequently need specialists' advice and support that can be challenging to deliver in a rural setting. The aim of this paper is to describe a model of integrated care in a rural area supported by a nurse case manager. Design/methodology/approach: A real-world evidence study of people living in Ribes de Freser nursing home, was conducted between specific timeframes in 2019 and 2022, comparing the casemix and outcomes of a traditional care model with the integrated interdisciplinary model. Findings: The integrated care model led to a significant reduction in transfers to the emergency department, hospitalisations, outpatient medical visits and a reduction in the number of medicines. In addition, the number of residents receiving end-of-life care at the nursing home showed a substantial increase. Originality/value: This case study contributes valuable evidence supporting the implementation of an integrated model of nurse case manager support in nursing homes, particularly in the rural contexts, where access to specialist medical staff may be limited. The findings highlight the potential benefits of person-centred integrated care for older adults, addressing their complex needs and improving end-of-life care in nursing home settings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. 3014 – ENDOTHELIAL-JAG2 PRESERVES HSC FUNCTION UPON AGING BY MAINTAINING HSC EPIGENETIC POLARITY THROUGH NOTCH SIGNALING ACTIVATION

Author

Matteini, Francesca, primary, Thambyrajah, Roshana, additional, Bartolome, Javier Lozano, additional, Perez, Alba Ferrer, additional, Mejia-Ramirez, Eva, additional, Vazquez, Sara Montserrat, additional, Molinero, Patricia Herrero, additional, Miranda, Jessica Gonzalez, additional, Bigas, Anna, additional, and Florian, Maria Carolina, additional

Published
2023
Full Text
View/download PDF

47. Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis

Author

Jaime E. Espinosa-Mora, Laura Nuzzolo-Shihadeh, Romulo Omar Flores-Pérez, Adrián Camacho-Ortiz, Eduardo Perez-Alba, marisela Mendoza-Garza, Juan Diego Lecona-Garcia, and Gloria Mayela Aguirre-García

Subjects
Male, Microbiology (medical), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Baricitinib, Hospitalized patients, medicine.medical_treatment, Microbiology, Dexamethasone, Internal medicine, Retrospective analysis, Humans, Immunology and Allergy, Medicine, Aged, Retrospective Studies, Mechanical ventilation, Sulfonamides, General Immunology and Microbiology, SARS-CoV-2, business.industry, COVID-19, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, QR1-502, COVID-19 Drug Treatment, Pneumonia, Infectious Diseases, Purines, Azetidines, Pyrazoles, Original Article, Drug Therapy, Combination, Female, business, medicine.drug
Abstract

Objective: We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy. Methodology: We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumonia (saturation

Published
2021

48. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

Author

Hugh Montgomery, F D Richard Hobbs, Francisco Padilla, Douglas Arbetter, Alison Templeton, Seth Seegobin, Kenneth Kim, Jesus Abraham Simón Campos, Rosalinda H Arends, Bryan H Brodek, Dennis Brooks, Pedro Garbes, Julieta Jimenez, Gavin C K W Koh, Kelly W Padilla, Katie Streicher, Rolando M Viani, Vijay Alagappan, Menelas N Pangalos, Mark T Esser, Wakana Abe, Tania Adan De Varona, Daria Adiatullina, Daniel Aguilar Zapata, Kevin Ahlers, Carolina Aimo, Ayoade Akere, Elena Akimova, Jorge Alatorre Alexander, Logan Aldrich, Ismael Ali Garcia, Karim Ali García, Lee Allison, Rosa Alonso Zuñiga, Ivan Aloysius, Javier Altclas, Andres Alvarisqueta, Martti Antila, Camila Anton, Elisabet Árboix Alamo, Samir Arora, Ramón Alejandro Avilés Felix, Natalya Bakhtina, Varenka Barbero-Becerra, Armando Barragan-Reyes, Alejandro Barreira, Mitchell Barrett, Jiri Beran, Nikolett Berki, Viktoria Berki, Richard Betten, Claudia Binelli, Lenka Brunzová, Cecilia Bussolari, Karianna Byargeon, Justyna Bytnar, Carlos Camberos, Pedro Campos Corzo, Grazia Cannon, Valentina Canovi, Simone Carla da Rosa, Ana Caroline Moser, Luis Carrera Rivas, Marcelo Martin Casas, Paulo Castañeda-Méndez, Ana Cavalcante, Eugenia Cherepova, Alexei Chermenskii, Lauren Clark, Mauro Codeluppi, Flavia Coelho, Belinda Contreras, Alex Cran, Taylor Dao, Chrisette Dharma, Cosimo Di Castri, Victoria Diaz Balocchi, Omar Durán, Kara Earl, Adam Ellery, Tomoko Endo, Andrea Everding, Rainald Fischer, Benedito Fonseca, Chelsea C. Franklin, Susan-Beatrice Franz, Anna Fumagalli, Mauricio Galindo-Amaya, Mariagiulia Galli, Laura Gerna, Karolly Gil Ureña, Henrikki Gomes Antila, Laura Ines Gomes Maricato, Gabriela Goncalvez, Martin Gonzalez, Jesús González-Lama, Stephen Granier, Jacob Granier, Stephan Grunwald, David Guardeño-Ropero, Monica Guberti, Sridhar Guduri, Carolina Guerrero García, Jehad Haggiagi, Kacie Hale, Toshimasa Hayashi, Maiara Hermes, Dante Hernandez Colin, Yuji Hirai, Masayuki Hojo, Tetsuya Homma, Billy Hour, Andreas Huber, Diego Iacovelli, Noriomi Ishibashi, Yutaro Iwabe, Shinyu Izumi, Arne Jessen, Heiko Jessen, Wilner Jeudy, Marta Jiménez Marcos, Rebecca Johnson, Eva Juárez-Hernández, Kiyomi Kabasawa, Katarzyna Kamińska, Megumi Kawabe, Angela Kemp, Oleg Khmelnitskiy, Carina Klassen, Olena Kobrynska, Pavel Koleckar, Stephanie Korn, Marc Kornmann, Viktor Kostenko, Evgenii Kovalchuk, Yana Kovalchuk, Tim Kümmerle, Ulrike Lachmund, Kerstin Lammersmann, Flávio Lastebasse, Ivana Lattuada, Felicitas Lauer, Kyrylo Lebed, Olga Lebed, Diego Lecona-Garcia, Maria Christina Leoni, Marina Lima, Raymond Little, Holly Little, Andrea Lizardi-Díaz, Michele Lobo-Becker, Francesco Luppi, Veronica Macias, Shigefumi Maesaki, Cristiano Magnaghi, Annalisa Mancini, Stanisław Mazur, Tatiana Melnikova, Sergio Menchaca, Ibrahim Menendez-Perez, Ewa Międlar, Shuuichi Mizunuma, Anastasiya Mochalova, Mihad Mohamed, Theresa Moll, Camila Montalvo, Amber Mottola, Birgit Mück, Rebeca Mussi Brugnolli, Akanksha Nanda, Dörthe Neuner, Agatha Ngwueke, Sebastian Noe, Martin Novacek, Laura Nuzzolo-Shihadeh, Emeka Obiekwe, Isaias G. Ocampo Gaytán, Norio Ohmagari, Shin Ohta, Ptuonye Onyewuchi, Iurii Pankov, Maurício Pedrosa, Yael Peré, Alejandro Pereyra, Eliana Perez, Eduardo Perez-Alba, Paloma Perpiña Lozano, Tanya Perrei, Dena Peterson, Ligia Pierroti, Felipe Pineda-Cárdenas, Teresa Plascencia Sanchez, Camila Poletti, Chiara Pomaranzi, Lisette Portes, Nils Postel, Monica Ramirez, Isabel Ramírez, Miguel Ramirez-Baena, Mahadev Ramjee, Giovanna Ratti, Jackie Reeve, Petr Reichert, Petra Reichertová, Edgar Alejandro Reyes Garcia, Celso Ricardo, Nicomedes Rodríguez Rodríguez, Jaun Roldán Sánchez, Matilde Romero-Lopez, Tyrone Rosales, Harvey Rosales, Mohamed Roshan, Simran Roshan, Patrizia Rovere Querini, Heather Rutter, Sadaf Sachwani, Hironori Sagara, Jun Sakai, Nina Samson, José Héctor Sánchez Mijangos, Liliana Sánchez, Ana Sánchez-González, Micko Sandford, Laura Santana, Felipe Santos de Carvalho, Reiko Sasao, Lubna Sato, Elizabeth Scheuermann, Olaf Schmidt, Masafumi Seki, Safia Shaikh, Daishi Shimada, Masaharu Shinkai, Masahiro Shinoda, Jackie Smith, Fernando Solorzano, Silvia Soncini, Katalin Soregine, Erica Sosa, Olalekan Sowade, Veronika Špinková, Ruth Staniford, Iska Steigemann, Vivien Steiner, Vladimir Strelkov, Cintya R. Suárez Pineda, Hiroki Suenaga, Shintaro Suzaki, Hannah Swayze, Yuji Tada, Yuichiro Takeshita, Yasuo Takiguchi, Akihiko Tanaka, Norihito Tarumoto, Albina Tatarintseva, Michelle Taubert, Elizaveta Terenya, César Tinoco, Tomohiro Tomiyasu, Gladys Torres-Vidal, Gabriela Trejo-Aguiar, Kenji Tsushima, Emma Tunstall, Caterina Turrà, Yoandy Valdes, Nelly Valencia Castro, Guilherme Visconti, Giordano Vitali, Apinya Vutikullird, Jezdancher Watti, Doreen Werth, Cheyanne Wilson, Philippe Wilson, Amy Workman, Pamela Wörle, Christoph Wyen, Yoshiko Yamaguchi, and Kei Yamamoto

Subjects
Adult, Pulmonary and Respiratory Medicine, Treatment Outcome, Double-Blind Method, SARS-CoV-2, Outpatients, Antibodies, Monoclonal, Humans, Middle Aged, COVID-19 Drug Treatment
Abstract

Background: Early intramuscular administration of SARS-CoV-2-neutralising monoclonal antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to moderate COVID-19 has potential to prevent disease progression. We aimed to evaluate the safety and efficacy of tixagevimab–cilgavimab in preventing progression to severe COVID-19 or death. Methods: TACKLE is an ongoing, phase 3, randomised, double-blind, placebo-controlled study conducted at 95 sites in the USA, Latin America, Europe, and Japan. Eligible participants were non-hospitalised adults aged 18 years or older with a laboratory-confirmed SARS-CoV-2 infection (determined by RT-PCR or an antigen test) from any respiratory tract specimen collected 3 days or less before enrolment and who had not received a COVID-19 vaccination. A WHO Clinical Progression Scale score from more than 1 to less than 4 was required for inclusion and participants had to receive the study drug 7 days or less from self-reported onset of mild to moderate COVID-19 symptoms or measured fever. Participants were randomly assigned (1:1) to receive either a single tixagevimab–cilgavimab 600 mg dose (two consecutive 3 mL intramuscular injections, one each of 300 mg tixagevimab and 300 mg cilgavimab) or placebo. Randomisation was stratified (using central blocked randomisation with randomly varying block sizes) by time from symptom onset, and high-risk versus low-risk of progression to severe COVID-19. Participants, investigators, and sponsor staff involved in the treatment or clinical evaluation and monitoring of the participants were masked to treatment-group assignments. The primary endpoints were severe COVID-19 or death from any cause through to day 29, and safety. This study is registered with ClinicalTrials.gov, NCT04723394. Findings: Between Jan 28, 2021, and July 22, 2021, 1014 participants were enrolled, of whom 910 were randomly assigned to a treatment group (456 to receive tixagevimab–cilgavimab and 454 to receive placebo). The mean age of participants was 46·1 years (SD 15·2). Severe COVID-19 or death occurred in 18 (4%) of 407 participants in the tixagevimab–cilgavimab group versus 37 (9%) of 415 participants in the placebo group (relative risk reduction 50·5% [95% CI 14·6–71·3]; p=0·0096). The absolute risk reduction was 4·5% (95% CI 1·1–8·0; p Interpretation: A single intramuscular tixagevimab–cilgavimab dose provided statistically and clinically significant protection against progression to severe COVID-19 or death versus placebo in unvaccinated individuals and safety was favourable. Treating mild to moderate COVID-19 earlier in the disease course with tixagevimab–cilgavimab might lead to more favourable outcomes.

Published
2022

49. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

Author

Montgomery, Hugh, primary, Hobbs, F D Richard, additional, Padilla, Francisco, additional, Arbetter, Douglas, additional, Templeton, Alison, additional, Seegobin, Seth, additional, Kim, Kenneth, additional, Campos, Jesus Abraham Simón, additional, Arends, Rosalinda H, additional, Brodek, Bryan H, additional, Brooks, Dennis, additional, Garbes, Pedro, additional, Jimenez, Julieta, additional, Koh, Gavin C K W, additional, Padilla, Kelly W, additional, Streicher, Katie, additional, Viani, Rolando M, additional, Alagappan, Vijay, additional, Pangalos, Menelas N, additional, Esser, Mark T, additional, Abe, Wakana, additional, Adan De Varona, Tania, additional, Adiatullina, Daria, additional, Aguilar Zapata, Daniel, additional, Ahlers, Kevin, additional, Aimo, Carolina, additional, Akere, Ayoade, additional, Akimova, Elena, additional, Alatorre Alexander, Jorge, additional, Aldrich, Logan, additional, Ali Garcia, Ismael, additional, Ali García, Karim, additional, Allison, Lee, additional, Alonso Zuñiga, Rosa, additional, Aloysius, Ivan, additional, Altclas, Javier, additional, Alvarisqueta, Andres, additional, Antila, Martti, additional, Anton, Camila, additional, Árboix Alamo, Elisabet, additional, Arora, Samir, additional, Avilés Felix, Ramón Alejandro, additional, Bakhtina, Natalya, additional, Barbero-Becerra, Varenka, additional, Barragan-Reyes, Armando, additional, Barreira, Alejandro, additional, Barrett, Mitchell, additional, Beran, Jiri, additional, Berki, Nikolett, additional, Berki, Viktoria, additional, Betten, Richard, additional, Binelli, Claudia, additional, Brunzová, Lenka, additional, Bussolari, Cecilia, additional, Byargeon, Karianna, additional, Bytnar, Justyna, additional, Camberos, Carlos, additional, Campos Corzo, Pedro, additional, Cannon, Grazia, additional, Canovi, Valentina, additional, Carla da Rosa, Simone, additional, Moser, Ana Caroline, additional, Carrera Rivas, Luis, additional, Casas, Marcelo Martin, additional, Castañeda-Méndez, Paulo, additional, Cavalcante, Ana, additional, Cherepova, Eugenia, additional, Chermenskii, Alexei, additional, Clark, Lauren, additional, Codeluppi, Mauro, additional, Coelho, Flavia, additional, Contreras, Belinda, additional, Cran, Alex, additional, Dao, Taylor, additional, Dharma, Chrisette, additional, Di Castri, Cosimo, additional, Diaz Balocchi, Victoria, additional, Durán, Omar, additional, Earl, Kara, additional, Ellery, Adam, additional, Endo, Tomoko, additional, Everding, Andrea, additional, Fischer, Rainald, additional, Fonseca, Benedito, additional, Franklin, Chelsea C., additional, Franz, Susan-Beatrice, additional, Fumagalli, Anna, additional, Galindo-Amaya, Mauricio, additional, Galli, Mariagiulia, additional, Gerna, Laura, additional, Gil Ureña, Karolly, additional, Gomes Antila, Henrikki, additional, Gomes Maricato, Laura Ines, additional, Goncalvez, Gabriela, additional, Gonzalez, Martin, additional, González-Lama, Jesús, additional, Granier, Stephen, additional, Granier, Jacob, additional, Grunwald, Stephan, additional, Guardeño-Ropero, David, additional, Guberti, Monica, additional, Guduri, Sridhar, additional, Guerrero García, Carolina, additional, Haggiagi, Jehad, additional, Hale, Kacie, additional, Hayashi, Toshimasa, additional, Hermes, Maiara, additional, Hernandez Colin, Dante, additional, Hirai, Yuji, additional, Hojo, Masayuki, additional, Homma, Tetsuya, additional, Hour, Billy, additional, Huber, Andreas, additional, Iacovelli, Diego, additional, Ishibashi, Noriomi, additional, Iwabe, Yutaro, additional, Izumi, Shinyu, additional, Jessen, Arne, additional, Jessen, Heiko, additional, Jeudy, Wilner, additional, Jiménez Marcos, Marta, additional, Johnson, Rebecca, additional, Juárez-Hernández, Eva, additional, Kabasawa, Kiyomi, additional, Kamińska, Katarzyna, additional, Kawabe, Megumi, additional, Kemp, Angela, additional, Khmelnitskiy, Oleg, additional, Klassen, Carina, additional, Kobrynska, Olena, additional, Koleckar, Pavel, additional, Korn, Stephanie, additional, Kornmann, Marc, additional, Kostenko, Viktor, additional, Kovalchuk, Evgenii, additional, Kovalchuk, Yana, additional, Kümmerle, Tim, additional, Lachmund, Ulrike, additional, Lammersmann, Kerstin, additional, Lastebasse, Flávio, additional, Lattuada, Ivana, additional, Lauer, Felicitas, additional, Lebed, Kyrylo, additional, Lebed, Olga, additional, Lecona-Garcia, Diego, additional, Leoni, Maria Christina, additional, Lima, Marina, additional, Little, Raymond, additional, Little, Holly, additional, Lizardi-Díaz, Andrea, additional, Lobo-Becker, Michele, additional, Luppi, Francesco, additional, Macias, Veronica, additional, Maesaki, Shigefumi, additional, Magnaghi, Cristiano, additional, Mancini, Annalisa, additional, Mazur, Stanisław, additional, Melnikova, Tatiana, additional, Menchaca, Sergio, additional, Menendez-Perez, Ibrahim, additional, Międlar, Ewa, additional, Mizunuma, Shuuichi, additional, Mochalova, Anastasiya, additional, Mohamed, Mihad, additional, Moll, Theresa, additional, Montalvo, Camila, additional, Mottola, Amber, additional, Mück, Birgit, additional, Mussi Brugnolli, Rebeca, additional, Nanda, Akanksha, additional, Neuner, Dörthe, additional, Ngwueke, Agatha, additional, Noe, Sebastian, additional, Novacek, Martin, additional, Nuzzolo-Shihadeh, Laura, additional, Obiekwe, Emeka, additional, Ocampo Gaytán, Isaias G., additional, Ohmagari, Norio, additional, Ohta, Shin, additional, Onyewuchi, Ptuonye, additional, Pankov, Iurii, additional, Pedrosa, Maurício, additional, Peré, Yael, additional, Pereyra, Alejandro, additional, Perez, Eliana, additional, Perez-Alba, Eduardo, additional, Perpiña Lozano, Paloma, additional, Perrei, Tanya, additional, Peterson, Dena, additional, Pierroti, Ligia, additional, Pineda-Cárdenas, Felipe, additional, Plascencia Sanchez, Teresa, additional, Poletti, Camila, additional, Pomaranzi, Chiara, additional, Portes, Lisette, additional, Postel, Nils, additional, Ramirez, Monica, additional, Ramírez, Isabel, additional, Ramirez-Baena, Miguel, additional, Ramjee, Mahadev, additional, Ratti, Giovanna, additional, Reeve, Jackie, additional, Reichert, Petr, additional, Reichertová, Petra, additional, Reyes Garcia, Edgar Alejandro, additional, Ricardo, Celso, additional, Rodríguez Rodríguez, Nicomedes, additional, Roldán Sánchez, Jaun, additional, Romero-Lopez, Matilde, additional, Rosales, Tyrone, additional, Rosales, Harvey, additional, Roshan, Mohamed, additional, Roshan, Simran, additional, Rovere Querini, Patrizia, additional, Rutter, Heather, additional, Sachwani, Sadaf, additional, Sagara, Hironori, additional, Sakai, Jun, additional, Samson, Nina, additional, Sánchez Mijangos, José Héctor, additional, Sánchez, Liliana, additional, Sánchez-González, Ana, additional, Sandford, Micko, additional, Santana, Laura, additional, Santos de Carvalho, Felipe, additional, Sasao, Reiko, additional, Sato, Lubna, additional, Scheuermann, Elizabeth, additional, Schmidt, Olaf, additional, Seki, Masafumi, additional, Shaikh, Safia, additional, Shimada, Daishi, additional, Shinkai, Masaharu, additional, Shinoda, Masahiro, additional, Smith, Jackie, additional, Solorzano, Fernando, additional, Soncini, Silvia, additional, Soregine, Katalin, additional, Sosa, Erica, additional, Sowade, Olalekan, additional, Špinková, Veronika, additional, Staniford, Ruth, additional, Steigemann, Iska, additional, Steiner, Vivien, additional, Strelkov, Vladimir, additional, Suárez Pineda, Cintya R., additional, Suenaga, Hiroki, additional, Suzaki, Shintaro, additional, Swayze, Hannah, additional, Tada, Yuji, additional, Takeshita, Yuichiro, additional, Takiguchi, Yasuo, additional, Tanaka, Akihiko, additional, Tarumoto, Norihito, additional, Tatarintseva, Albina, additional, Taubert, Michelle, additional, Terenya, Elizaveta, additional, Tinoco, César, additional, Tomiyasu, Tomohiro, additional, Torres-Vidal, Gladys, additional, Trejo-Aguiar, Gabriela, additional, Tsushima, Kenji, additional, Tunstall, Emma, additional, Turrà, Caterina, additional, Valdes, Yoandy, additional, Valencia Castro, Nelly, additional, Visconti, Guilherme, additional, Vitali, Giordano, additional, Vutikullird, Apinya, additional, Watti, Jezdancher, additional, Werth, Doreen, additional, Wilson, Cheyanne, additional, Wilson, Philippe, additional, Workman, Amy, additional, Wörle, Pamela, additional, Wyen, Christoph, additional, Yamaguchi, Yoshiko, additional, and Yamamoto, Kei, additional

Published
2022
Full Text
View/download PDF

50. Pearls & Oy-sters: Challenges and Controversies in Wilson Disease

Author

Ruiz-Lopez, Marta, primary, Moreno Estébanez, Ana, additional, Tijero, Beatriz, additional, Fernandez, Tamara, additional, Rebollo-Perez, Alba, additional, Gabilondo, Iñigo, additional, Lopez-Osle, Nuria, additional, Ceberio-Hualde, Leticia, additional, Zarranz, Juan Jose, additional, and Gomez-Esteban, Juan Carlos, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results